DE102006008774A1 - Device for conveying a regenerative tissue process for treating joint arthrosis and complicated fractures and soft tissue damage comprises primary light sources and a holder for holding the light sources - Google Patents
Device for conveying a regenerative tissue process for treating joint arthrosis and complicated fractures and soft tissue damage comprises primary light sources and a holder for holding the light sources Download PDFInfo
- Publication number
- DE102006008774A1 DE102006008774A1 DE102006008774A DE102006008774A DE102006008774A1 DE 102006008774 A1 DE102006008774 A1 DE 102006008774A1 DE 102006008774 A DE102006008774 A DE 102006008774A DE 102006008774 A DE102006008774 A DE 102006008774A DE 102006008774 A1 DE102006008774 A1 DE 102006008774A1
- Authority
- DE
- Germany
- Prior art keywords
- light sources
- light
- holding
- joint
- joint space
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims description 19
- 238000000034 method Methods 0.000 title abstract description 3
- 230000001172 regenerating effect Effects 0.000 title abstract 2
- 210000001519 tissue Anatomy 0.000 title description 4
- 206010010149 Complicated fracture Diseases 0.000 title 1
- 210000004872 soft tissue Anatomy 0.000 title 1
- 230000000451 tissue damage Effects 0.000 title 1
- 231100000827 tissue damage Toxicity 0.000 title 1
- 206010031264 Osteonecrosis Diseases 0.000 claims description 11
- 239000013307 optical fiber Substances 0.000 claims description 11
- 230000005855 radiation Effects 0.000 claims description 9
- 230000000877 morphologic effect Effects 0.000 claims description 2
- 238000000149 argon plasma sintering Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 3
- 210000003321 cartilage cell Anatomy 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010017815 Gastric perforation Diseases 0.000 description 1
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
Abstract
Description
Die Erfindung betrifft eine Vorrichtung zur Behandlung von Gelenkarthrosen in einem Gelenkspalt und Knochennekrosen in einem Gelenkbereich.The The invention relates to a device for the treatment of joint arthrosis in a joint space and bone necrosis in a joint area.
Die heutigen medikamentösen Behandlungstherapien für Arthrose und ähnliche Krankheiten sind ausschließlich symptomgesteuert. Das therapeutische Ziel ist es, eine aktivierte oder aktuell schmerzhafte Arthrose/Osteonekrose in einen stummen Zustand zu überführen, in dem schmerzarme Bewegungen wieder möglich sind. Es gibt bis heute keinen therapeutischen Weg, Arthrosen/Osteonekrosen dauerhaft zu heilen. Unter anderem liegt dies darin begründet, dass die Ursachen primärer Arthrosen oder Osteonekrosen im Detail nicht bekannt sind. Nach der medikamentösen Therapie erfolgt im weiteren Krankheitsverlauf nahezu unabdingbar die operative Therapie, d.h. der künstliche Gelenkersatz.The today's medicinal Treatment therapies for Osteoarthritis and similar Diseases are exclusive symptom control. The therapeutic goal is to have one activated or currently painful osteoarthritis / osteonecrosis in a mute State to convict, in the painless movements are possible again. There is no one today Therapeutic way to cure arthrosis / osteonecrosis permanently. Among other things, this is due to the fact that the causes of primary arthrosis or Osteonecroses are not known in detail. After drug therapy In the further course of the disease, operative treatment is almost indispensable Therapy, i. the artificial one Joint replacement.
Die medikamentösen Therapien basieren auf der Injektion von Analgetika, nichtsteroidalen Anthirheumatika oder Glukokortikoiden. Die am meisten therapeutisch eingesetzten nichtsteroidalen Anthirheumatika (NSAR) sind bei Langzeitanwendungen, wie sie bei Arthrosen erforderlich sind, sehr stark von Nebenwirkungen behaftet. Gefährliche Komplikationen sind Magengeschwüre, Magenblutungen, Magendurchbrüche, schwere Nieren- oder Leberschäden. So bekommen 15–20% der Arthrosepatienten ein Magengeschwür, 1–3% müssen wegen Magenblutungen- und Durchbrüchen stationär behandelt werden. Selbst Todesfälle als Folge der Verwendung nichtsteriodaler Antirheumatika werden berichtet.The drug Therapies based on the injection of analgesics, nonsteroidal Anthraheumatics or glucocorticoids. The most therapeutic non-steroidal anti-inflammatory drugs (NSAIDs) used in long-term use, as they are needed in arthrosis, very much from side effects afflicted. Dangerous complications are stomach ulcers, Stomach bleeding, gastric perforations, severe kidney or liver damage. So get 15-20% the osteoarthritis patient has a gastric ulcer, 1-3% and breakthroughs stationary be treated. Even deaths as a result of the use of non-steroidal anti-inflammatory drugs reported.
Neuere Medikamente der NSAR-Gruppe sind sogenannte COX-2-Hemmer, die etwas weniger nebenwirkungsbehaftet sind, aber bei Patienten mit geschwächtem Herz-Kreislauf System, also bei allen älteren Patienten, d.h. bei 80% aller Arthrosepatienten, das Risiko für kardiovaskuläre Ereignisse, wie zum Beispiel einem Herzinfarkt, deutlich erhöhen. Es muss betont werden, dass der risikoreiche Einsatz dieser Medikamente in keinem Fall auf eine Heilung der Arthrose gerichtet ist, sondern nur auf eine Verlangsamung des Arthroseverlaufes.newer Medications of the NSAID group are called COX-2 inhibitors, which is something less side effects, but in patients with a weakened cardiovascular system, So with all older ones Patients, i. in 80% of all osteoarthritis patients, the risk of cardiovascular events, such as a heart attack, increase significantly. It has to be emphasized that the risky use of these drugs in any case aimed at a cure of osteoarthritis, but only one Slowing of the arthritis course.
Die dritte medikamentöse Gruppe, die Glukokortikoide, weisen ebenfalls starke Nebenwirkungen auf. Sie sind dem im Körper gebildeten Hormon Kortison verwandt und haben eine stark entzündungshemmende Wirkung. Bei Arthrosepatienten werden intraartikuläre Glukokortikoidinjektionen vorgenommen, um die typischen Nebenwirkungen dieser Medikamentengruppe, wie vor allem Knochenschwund, zu begrenzen. Neuerdings werden Knorpelschutzpräparate getestet, die auf Glucosalminsulfat, Chondritinsulfat, Hyalonsäure und Interleukin-1 Rezeptorantagonist basieren. Neuerdings werden Knorpelschutzpräparate getestet, die auf Glucosaminsulfat, Chondroitinsulfat, Hyaluronsäure und Interleukin-1 Rezeptorantagonist basieren. Nachweise für die Wirksamkeit dieser Medikamente liegen derzeit nicht vor.The third drug Group, the glucocorticoids, also have strong side effects on. They are in the body hormone cortisone related and have a strong anti-inflammatory Effect. In osteoarthritis patients, intra-articular glucocorticoid injections are used made to the typical side effects of this group of drugs, as especially bone loss, limit. Recently, cartilage protection products have been tested on glucosalmine sulfate, chondritin sulfate, hyalonic acid and Interleukin-1 receptor antagonist based. Recently, cartilage protection products have been tested Glucosamine sulfate, chondroitin sulfate, hyaluronic acid and Interleukin-1 receptor antagonist based. Evidence of effectiveness These medicines are currently not available.
Die nach der medikamentösen Phase sehr häufig erforderliche operative Phase erfolgt in verschiedenen Stufen. Zunächst wird versucht, mittels Knochen-Knorpel-Transplantationen, Bioprothesen sowie der autologen Chondrozyten-Transplatation Verbesserungen der Gelenkfunktion zu erreichen, die auf körpereigenen Mechanismen aufbauen. Dies wird in der Regel begleitet durch achsenkorrigierende Maßnahmen, wie z.B. der Osteotomie, um Gelenkfehlstellungen zu reduzieren. Die finale Therapie der Arthrose oder Osteonekrose ist nach heutigem Stand der Technik die Endoprothese, d.h. der künstliche Gelenkersatz.The after the medicinal Phase very often The required operational phase takes place in various stages. First, will tried using bone-cartilage transplants, bioprostheses as well Autologous chondrocyte transplants improve joint function to achieve that on the body's own Build mechanisms. This is usually accompanied by axis-correcting Activities, such as. osteotomy to reduce joint deformity. The final therapy of osteoarthritis or osteonecrosis is to date In the art, the endoprosthesis, i. the artificial joint replacement.
Es wird also deutlich, dass die derzeit bekannten Vorgehensweisen bei der Behandlung von Gelenkarthrosen bzw. Knochennekrosen nicht in der Lage sind, eine wirkungsvolle Therapie dieser Krankheiten zu bieten. Von einer Heilung der in Rede stehenden Krankheiten sind diese Behandlungsarten jedoch äußerst weit entfernt.It So it becomes clear that the currently known approaches to the treatment of joint arthrosis or bone necrosis not in are able to provide effective therapy for these diseases Offer. Of a cure of the diseases in question are However, these types of treatment extremely far away.
Es ist daher Aufgabe der vorliegenden Erfindung, eine Vorrichtung zur Behandlung von Gelenkarthrosen und Knochennekrosen zu schaffen, welche eine nicht medikamentöse und damit nebenwirkungsfreie und dennoch medizinisch wirkungsvolle Behandlung dieser Krankheiten ermöglicht.It is therefore an object of the present invention, a device for To provide treatment for joint arthrosis and bone necrosis which is a non-drug and thus treatment without side effects and yet medically effective allows these diseases.
Erfindungsgemäß wird diese Aufgabe durch die in Anspruch 1 genannten Merkmale gelöst.According to the invention this Problem solved by the features mentioned in claim 1.
Durch die erfindungsgemäße Vorrichtung wird punktförmiges Licht in den betroffenen Gelenkspalt eingeleitet, sodass sich in dem Gelenkspalt eine hohe Lichtdichte und ein homogenes Lichtfeld ergeben. Dadurch konnten klinisch manifestierbare Verbesserungen der Arthrose bzw. Nekrose bis hin zu einer vollständigen Heilung dieser Krankheiten festgestellt werden. Durch dieses Einleiten von Licht in den Gelenkspalt ergibt sich erfindungsgemäß eine intensive Wechselwirkung der Photonen mit den Gewebestrukturen der Gelenke, insbesondere mit den Knochenzellen, den Knorpelzellen, den die Knochen- und Knorpelzellen ernährenden Endotelzel len sowie den vaskulären Strukturen im Knochen und Muskelgewebe.By the device according to the invention is punctate Light is introduced into the affected joint space, so that in give the joint gap a high light density and a homogeneous light field. This allowed clinically manifestable improvements in osteoarthritis or necrosis up to a complete cure of these diseases become. By this introduction of light into the joint gap results according to the invention an intensive Interaction of the photons with the tissue structures of the joints, especially with the bone cells, cartilage cells, the bone and Nourishing cartilage cells Endocells and the vascular Structures in the bone and muscle tissue.
Die erfindungsgemäße Vorrichtung wirkt grundsätzlich nicht-invasiv, so dass sich keinerlei Beschädigungen oder gar Zerstörungen der Gewebe- oder Gelenkstruktur ergeben. Vielmehr wurden in entsprechenden Versuchen bereits große Heilerfolge erzielt, wobei keinerlei Nebenwirkungen zu verzeichnen waren. Da durch die erfindungsgemäße Vorrichtung erhebliche Operationskosten einschließlich der nicht mehr erforderlichen künstlichen Gelenke eingespart werden können, ist mit derselben auch ein erheblicher volkswirtschaftlicher Nutzen verbunden.The inventive device is basically non-invasive, so that no damage or even destruction of the tissue or joint structure arise. Rather, were in corresponding attempts have already achieved great healing success, with no side effects were recorded. As can be saved by the inventive device considerable operating costs including no longer required artificial joints, is associated with the same, a significant economic benefits.
Hierbei dient die erfindungsgemäße Halteeinrichtung zum einfachen Anordnen der das punktförmige Licht ausstrahlenden Lichtquellen gegenüber dem zu behandelnden Patienten, was zu einer sehr einfachen Anwendung der erfindungsgemäßen Vorrichtung führt.in this connection serves the holding device according to the invention for easy placement of the point-shaped light emitting Light sources opposite the patients to be treated, resulting in a very simple application the device according to the invention leads.
Wenn in einer vorteilhaften Weiterbildung der Erfindung die Lichtquellen linear entlang bzw. über dem betroffenen Gelenkspalt oder Gelenkbereich angeordnet sind, so ergibt sich ein sehr homogenes, zweidimensionales Lichtfeld hoher Lichtdichte innerhalb des Gelenkspalts, das den Gelenkspalt oder das Gelenkareal flächenförmig ausfüllt, wodurch eine besonders inten sive Bestrahlung der betroffenen Bereiche gewährleistet ist.If in an advantageous embodiment of the invention, the light sources linear along or above the Affected joint space or joint area are arranged so gives a very homogeneous, two-dimensional light field of high light density within the joint space, which is the joint space or joint area fills out flat, causing ensures a particularly intensive irradiation of the affected areas is.
Eine derartiges sehr homogenes, zweidimensionales Lichtfeld hoher Lichtdichte lässt sich beispielsweise dadurch erreichen, dass der Abstand der einzelnen Lichtquellen maximal dem Durchmesser des auf der Haut des Patienten erzeugten Lichtflecks entspricht.A Such a very homogeneous, two-dimensional light field of high light density can be, for example achieve that the distance between the individual light sources maximum the diameter of the light spot produced on the patient's skin equivalent.
Wenn in einer weiteren vorteilhaften Ausführungsform der Erfindung die Lichtquellen mit der Haut des Patienten in Berührung stehen, so werden Reflexionsverluste vermieden und die Leistung der Lichtquellen kann optimal umgesetzt werden.If in a further advantageous embodiment of the invention the Light sources are in contact with the skin of the patient, so are reflection losses avoided and the performance of the light sources can be optimally implemented become.
Als für die praktische Anwendung besonders geeignet hat sich ein Licht mit einer Wellenlänge von 600 bis 850 nm erwiesen.When for the practical application has a light with a suitable wavelength from 600 to 850 nm proved.
Eine besonders flexible Anbringung der Lichtquellen an dem Patienten, auch im Hinblick auf die unterschiedlichen Körperpartien, die behandelt werden können, ergibt sich, wenn die Halteeinrichtung als an den zu behandelnden Ort des Patienten anpassbare Manschette ausgebildet ist, welche einzelne Haltenoppen zum Aufnehmen der Lichtquelle aufweist.A particularly flexible attachment of the light sources to the patient, also with regard to the different body parts that are treated can, arises when the holding device as to be treated Location of the patient customizable cuff is formed which single holding nubs for receiving the light source has.
Des weiteren kann vorgesehen sein, dass die Haltenoppen an ihrer Innenseite Vorsprünge zum Halten der Lichtquelle aufweisen. Mittels derartiger Vorsprünge ist ein sicherer Halt der Lichtquellen an der Halteeinrichtung gewährleistet.Of further it can be provided that the holding nubs on its inside projections to hold the light source. By means of such projections ensures a secure hold of the light sources on the holding device.
Weitere vorteilhafte Ausgestaltungen und Weiterbildungen der Erfindung ergeben sich aus den restlichen Unteransprüchen. Nachfolgend werden Ausführungsbeispiele der Erfindung anhand der Zeichnung prinzipmäßig dargestellt.Further yield advantageous embodiments and refinements of the invention from the remaining subclaims. Hereinafter, embodiments of the invention shown in principle with reference to the drawing.
Es zeigt:It shows:
Die
Anzahl und die Anordnung der Haltenoppen
In
In
dem Schnitt von
Zum
Halten der optischen Fasern
Bei
der Ausführungsform
der Vorrichtung
Im
Gegensatz zu der Ausführungsform
von
Bei
der Ausführungsform
der Vorrichtung
Mit
der Vorrichtung
Der
größte Anwendungsbereich
für die
Vorrichtung
Die
Vorrichtung
Die
Vorrichtung
Claims (16)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006008774A DE102006008774A1 (en) | 2006-02-24 | 2006-02-24 | Device for conveying a regenerative tissue process for treating joint arthrosis and complicated fractures and soft tissue damage comprises primary light sources and a holder for holding the light sources |
DE202006017153U DE202006017153U1 (en) | 2006-02-24 | 2006-11-08 | Device for promoting regenerative tissue processes |
PCT/EP2007/001530 WO2007098883A2 (en) | 2006-02-24 | 2007-02-22 | Device for the promotion of regenerative tissue processes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006008774A DE102006008774A1 (en) | 2006-02-24 | 2006-02-24 | Device for conveying a regenerative tissue process for treating joint arthrosis and complicated fractures and soft tissue damage comprises primary light sources and a holder for holding the light sources |
DE202006017153U DE202006017153U1 (en) | 2006-02-24 | 2006-11-08 | Device for promoting regenerative tissue processes |
Publications (1)
Publication Number | Publication Date |
---|---|
DE102006008774A1 true DE102006008774A1 (en) | 2007-09-06 |
Family
ID=37776268
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE102006008774A Withdrawn DE102006008774A1 (en) | 2006-02-24 | 2006-02-24 | Device for conveying a regenerative tissue process for treating joint arthrosis and complicated fractures and soft tissue damage comprises primary light sources and a holder for holding the light sources |
DE202006017153U Expired - Lifetime DE202006017153U1 (en) | 2006-02-24 | 2006-11-08 | Device for promoting regenerative tissue processes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE202006017153U Expired - Lifetime DE202006017153U1 (en) | 2006-02-24 | 2006-11-08 | Device for promoting regenerative tissue processes |
Country Status (2)
Country | Link |
---|---|
DE (2) | DE102006008774A1 (en) |
WO (1) | WO2007098883A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010029350A1 (en) * | 2010-05-27 | 2011-12-01 | Detlef Schikora | Cosmetic, non-therapeutic method for irradiating the skin and device for irradiating the skin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081128B2 (en) * | 2002-03-04 | 2006-07-25 | Hart Barry M | Phototherapy device and method of use |
US6860896B2 (en) * | 2002-09-03 | 2005-03-01 | Jeffrey T. Samson | Therapeutic method and apparatus |
US6991644B2 (en) * | 2002-12-12 | 2006-01-31 | Cutera, Inc. | Method and system for controlled spatially-selective epidermal pigmentation phototherapy with UVA LEDs |
US8083784B2 (en) * | 2003-08-19 | 2011-12-27 | Photonx Health Corporation | Photon therapy method and apparatus |
DE102004032394A1 (en) * | 2004-07-03 | 2006-01-19 | Weber, Michael, Dr. | Laser needle for performing a combined laser needle electroacupuncture |
-
2006
- 2006-02-24 DE DE102006008774A patent/DE102006008774A1/en not_active Withdrawn
- 2006-11-08 DE DE202006017153U patent/DE202006017153U1/en not_active Expired - Lifetime
-
2007
- 2007-02-22 WO PCT/EP2007/001530 patent/WO2007098883A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2007098883A3 (en) | 2008-02-21 |
DE202006017153U1 (en) | 2007-02-15 |
WO2007098883A2 (en) | 2007-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69631294T2 (en) | TENSIONING ELEMENT / STOP FOR FRAGMENTS | |
DE69937876T2 (en) | PIN TO BONE FIXATION | |
DE60033915T2 (en) | ENDOVASCULAR LASER DEVICE FOR THE TREATMENT OF VARICOSE VEINS | |
DE60118256T2 (en) | Implant with adhesive material | |
US9795802B2 (en) | Method of orthopedic treatment by radiation | |
DE102011052002B4 (en) | Laser therapy system with UVA and IR laser light for the directed generation of a dermal collagen matrix | |
DE60215744T2 (en) | Self-tapping bone screw with two components | |
EP2340777B1 (en) | Osteosynthesis plate for fractures near joints or osteotomies | |
DE69934516T2 (en) | AXIAL INTRAMEDULAR SCREW FOR OSTEOSYNTHESIS OF LONG BONE | |
DE69725596T2 (en) | ELECTROMAGNETIC HEART BIOSTIMULATION | |
CH672739A5 (en) | ||
WO1998052512A1 (en) | Use of a sound pulse source | |
EP1337298B1 (en) | Device for performing acupuncture using laser radiation | |
DE10128629A1 (en) | Skin plaster for wounds incorporates an opening which provides access to the wound, and is provided with a cover letting through light or radiation | |
WO2005009538A2 (en) | Acupuncture device using a laser beam | |
DE102006008774A1 (en) | Device for conveying a regenerative tissue process for treating joint arthrosis and complicated fractures and soft tissue damage comprises primary light sources and a holder for holding the light sources | |
DE202016008331U1 (en) | Device for influencing biological processes in a living tissue | |
DE1239089B (en) | Process for increasing the absorption capacity of collagen products in the living body | |
Witte | Treating canine patellar ligament rupture | |
DE102008010890A1 (en) | Human skin treatment device e.g. perforation device, for e.g. treatment of corneal layer disturbances, has injecting unit provided for injecting energy into skin, and attached to support adjacent to mechanical treatment unit | |
RU2345735C1 (en) | Method of treating acute aseptic tendovaginitis of interosseous muscle in training horses | |
EP1948311B1 (en) | Device for the medical treatment of patients | |
Sauerbier et al. | Pedicled vascularized bone grafts from the dorsum of the distal radius for treatment of scaphoid nonunions | |
AT406547B (en) | Laser device | |
Sinan et al. | Radiological study of the influence of platelet rich-plasma and low level laser therapy on healing of experimentally fractured proximal sesamoid bone in equine: Part Ι1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8139 | Disposal/non-payment of the annual fee |